¹Ù·Î°¡±â ¸Þ´º

¹Ù·Î°¡±â ¸Þ´º º»¹®³»¿ë ¹Ù·Î°¡±â ¸ÞÀθ޴º ¹Ù·Î°¡±â

ÁÖ¿ä¾È³»

HOME »çÀÌÆ®¸Ê

FONT SIZE

ÆùƮũ±â Å°¿ò 100% 110% 120% 130% 140% ÆùƮũ±â ÁÙÀÓ
¸Þ´ºº¸±â
 
Á¦¸ñ
7/15 ¹ßÇ¥ ³í¹®ÀÔ´Ï´Ù.
ÀÛ¼ºÀÏ
2023-07-12
Á¶È¸¼ö
195


¾È³çÇϼ¼¿ä 7/15 ¹ßÇ¥ÀÚ ¿äÇÑÀÔ´Ï´Ù.

Á¦°¡ ¹ßÇ¥ÇÒ ³í¹®Àº 2022³â Annals of the Rheumatic Diseases¿¡ ÃâÆǵÈ
TFH cells with NLRP3 inflammasome activation are essential for high-affinity antibody generation, germinal center formation and autoimmunity’ÀÔ´Ï´Ù.

IL-1β´Â normal immunization°ú autoimmunityÀÇ antibody response¿¡ ±â¿©ÇÑ´Ù°í ¾Ë·ÁÁ® ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ IL-1β´Â NLRP3 inflammasome¿¡ ÀÇÇÑ caspase-1ÀÇ È°¼ºÀ¸·ÎºÎÅÍ Çü¼ºµÈ´Ù°íµµ Àß ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù.

¶ÇÇÑ IL-1β°¡ CD4+ T cell¿¡¼­ antigen driven expansion°ú differentiationÀ» °­È­ÇÑ´Ù°íµµ ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù¸¸, CD4+ T cell¿¡¼­ »ý¼ºµÇ´Â IL-1βÀÇ ¿ªÇÒ¿¡ ´ëÇÑ ¿¬±¸°¡ ºÎÁ·ÇÑ ½ÇÁ¤ÀÔ´Ï´Ù.

ÀÌ¿¡ º» ¿¬±¸ÆÀÀº NLRP3 activationÀÌ TFH cellÀÇ T dependentÇÑ antigen¿¡ ´ëÇÑ humoral response¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù´Â °ÍÀ» ¹àÇû½À´Ï´Ù.

±× ¹æ¹ýÀ¸·Î´Â NLRP3¿¡ specificÇÑ inhibitorÀÎ MCC950À» »ç¿ëÇÏ¿© immunizationµÈ mouseÀÇ Germinal center, spleen ¹× antibody secretion °ú affinity maturation µîÀ» ÆľÇÇÏ¿´À¸¸ç,

B6.NLRP3fl/flCreLCK ¸¶¿ì½º ¸ðµ¨À» »ç¿ëÇÏ¿© IgM, IgGÀÇ affinity maturation°ú antibody response µîÀ» È®ÀÎÇÏ¿´½À´Ï´Ù.

¸¶Áö¸·À¸·Î ÀÌ·¯ÇÑ NLRP3 inflammasomeÀÌ autoimmunity¿¡¼­´Â ¾î¶°ÇÑ ¿ªÇÒÀ» È®ÀÎÇϱâ À§ÇØ SLE mouse modelÀÎ MRL/lpr ¸¶¿ì½º¿¡¼­ NLRP3ÀÇ È°¼ºÀ» È®ÀÎÇÏ°í, MCC950À» ó¸®ÇÏ¿© Áúº´ÀÇ parameter µîÀÇ ¿ÏÈ­¸¦ °üÂûÇÏ¿´½À´Ï´Ù.

¶ÇÇÑ SLE patientÀÇ PBMC¸¦ ÅëÇØ SLE patientµéÀÇ TFH¿¡¼­ ³ôÀº NLRP3 inflammasome activationÀ» È®ÀÎÇÏ¿´À¸¸ç, Ãß°¡ÀûÀ¸·Î hydroxychloroquine µîÀÇ immunosuppressive ¾à¹°À» Åõ¿©ÇÑ È¯ÀÚ¿¡¼­ ÀÌ·¯ÇÑ NLRP3 inflammasome activationÀÌ °¨¼ÒÇÏ´Â °Í ¶ÇÇÑ ¹ß°ßÇÏ¿´½À´Ï´Ù.

À§ ³í¹®À» °øºÎÇÑ ÀÌÀ¯´Â, ÃÖ±Ù NLRP3 inflammasome¿¡ ´ëÇؼ­ °øºÎÇϸç, ÀÌ·¯ÇÑ inflammasomeÀÌ macrophage, monocytes, DC»Ó¸¸ ¾Æ´Ï¶ó CD4+ T cell¿¡¼­µµ Çü¼ºµÇ¸ç humoral immune response¿¡ °ü¿©ÇÑ´Ù´Â °ÍÀ» ¾Ë°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ °ü½É ÀÖ´Â ÁÖÁ¦ Áß ÇϳªÀÎ autoimmune condition¿¡¼­ ÀÌ·¯ÇÑ CD4+ T cellÀÇ NLRP3 inflammasomeÀÌ ¾î¶°ÇÑ ¿µÇâÀ» ¹ÌÄ¡´ÂÁö °øºÎÇϱâ À§Çؼ­ ¼±Á¤ÇÏ°Ô µÇ¾ú½À´Ï´Ù.

¿­½ÉÈ÷ ÁغñÇÏ¿© Åä¿äÀÏ¿¡ ºË°Ú½À´Ï´Ù.

°¨»çÇÕ´Ï´Ù.

±è¿äÇÑ ¿Ã¸²

³í¹® ¸µÅ©: ¹Ù·Î °¡±â
 
÷ºÎÆÄÀÏ:
÷ºÎÆÄÀÏÀÌ ¾ø½À´Ï´Ù.
´ÙÀ½±Û
7/15 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä, À̹øÁÖ ¹ßÇ¥ÀÚ ¼öÁöÀÔ´Ï´Ù. Á¦°¡ ¼±Á¤ÇÑ ³í¹®Àº ¿ÃÇØ Cell reports ¿¡ ÃâÆÇµÈ "Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination" ÀÔ´Ï´Ù. º» ³í¹®Àº epidemics ¸¦ ÀÏÀ¸Å°´Â betacoronavirus (sarbecoviruses) ¸¦ ¿¬±¸ÇÑ ³í¹®À¸·Î,cross-sarbecovirus protectiv..
ÀÌÀü±Û
7/8 ¹ßÇ¥ ³í¹®ÀÔ´Ï´Ù.
/ °ü¸®ÀÚ
¾È³çÇϼ¼¿ä, µµºóÀÔ´Ï´Ù. À̹ø¹ßÇ¥ÇÒ ³í¹®Àº Áö³­ 26ÀÏ nature immunology¿¡ ÃâÆÇµÈ 'Distinct metabolic requirements regulate B cell activation and germinal center responses' ÀÔ´Ï´Ù. ÀϹÝÀûÀ¸·Î non-proliferating cell Àº glucose °¡ pyruvate ·Î ÀüȯµÇ¸é mitochondria È£ÈíÀ» ÅëÇÑ OXPHOS ·Î ¿¡³Ê..